Medannex: monoclonal antibody MDX 124 highly active in pancreatic cancer models

Released: Friday 21st January 2022

Medannex’s monoclonal antibody MDX-124 highly active
in pancreatic cancer models

Medannex has just presented new data at ASCO GI showing that our first-in-class annexin-A1 monoclonal antibody (MDX-124) has significant anti-tumour activity in pancreatic cancer models, and synergy with two further widely-used chemotherapies.

The new data demonstrate that MDX-124:

  • Significantly reduces cancer cell proliferation via cell cycle arrest
  • Has strong synergy with 5-FU and gemcitabine
  • Significantly decreases cancer cell migration
  • Reduces both the incidence and burden of lung metastases
  • Increases primary tumour necrosis

Based on this, and the data we presented last month at the San Antonio Breast Cancer Symposium, MDX-124 has great potential to improve outcomes for patients and we’re looking forward to exploring this further in our imminent First-in-Human study.

For full details please click here.



Medannex CEO Ian Abercrombie


- ENDS -

Medannex Ltd enquiries – email

View all News